In a 70‑year‑old man with type 2 diabetes, hypertension, and hyperlipidemia who is taking insulin glargine (Lantus) 10 units nightly, dapagliflozin (Farxiga) 10 mg daily, and sitagliptin/metformin XR (Janumet XR) 100 mg/1000 mg daily, with a current HbA1c of 9.5% (up from 8.8%) and an average glucose of 172 mg/dL on continuous glucose monitoring, what is the safest initial step to improve his glycemic control?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Increase Lantus Aggressively and Add Prandial Insulin Coverage

For this 70-year-old man with an HbA1c of 9.5% (up from 8.8%) and average glucose of 172 mg/dL on only 10 units of Lantus nightly, the current basal insulin dose is profoundly inadequate and requires immediate aggressive titration; simultaneously, prandial insulin should be added because basal insulin alone will not achieve glycemic targets at this level of hyperglycemia.

Immediate Basal Insulin Titration

  • Increase Lantus by 4 units every 3 days until fasting glucose consistently reaches 80–130 mg/dL, because fasting glucose values in the 170s mg/dL warrant the more aggressive 4-unit increment rather than the standard 2-unit increase used for fasting glucose 140–179 mg/dL. 1

  • For a 70-year-old patient (approximately 70 kg), the recommended starting dose for insulin-naïve patients is 0.1–0.2 units/kg/day (7–14 units), but with an HbA1c of 9.5%, the total daily insulin requirement is likely 0.3–0.5 units/kg/day (21–35 units total), split between basal and prandial components. 1, 2

  • Stop basal escalation when Lantus approaches 0.5 units/kg/day (approximately 35 units for a 70-kg patient) without achieving glycemic targets, because further basal increases lead to "over-basalization" with increased hypoglycemia risk and suboptimal control. 1, 2

Add Prandial Insulin Immediately

  • Start rapid-acting insulin (lispro, aspart, or glulisine) at 4 units before each of the three largest meals, or alternatively use 10% of the current basal dose (which will increase as Lantus is titrated). 1, 2

  • Administer prandial insulin 0–15 minutes before meals for optimal post-prandial glucose control. 1, 2

  • Titrate each meal dose by 1–2 units every 3 days based on 2-hour post-prandial glucose readings, targeting post-prandial glucose <180 mg/dL. 1, 2

Rationale for Aggressive Approach

  • An HbA1c of 9.5% that has increased from 8.8% despite being on Lantus indicates both inadequate basal coverage AND uncontrolled post-prandial hyperglycemia, necessitating combined basal-bolus therapy rather than basal-only titration. 1

  • With properly implemented basal-bolus therapy, approximately 68% of patients achieve mean glucose <140 mg/dL, compared with only 38% when dosing is inadequate or when sliding-scale insulin alone is used. 1, 2

  • An HbA1c reduction of 2–3% (from 9.5% to approximately 7–7.5%) is achievable within 3–6 months with intensive insulin titration combined with the patient's existing oral agents. 1, 2

Continue and Optimize Oral Agents

  • Continue Farxiga 10 mg daily because SGLT2 inhibitors provide complementary glucose-lowering through an insulin-independent mechanism, reduce cardiovascular events, and facilitate weight loss. 3, 4, 5

  • Continue Janumet XR 100-1000 mg daily (sitagliptin/metformin combination) because metformin reduces total insulin requirements by 20–30% and provides superior glycemic control when combined with insulin. 1, 2

  • Consider increasing metformin to 1000 mg twice daily (2000 mg total) if the patient is currently on only 1000 mg daily, because the maximum effective dose is up to 2500 mg/day and higher doses provide additional glucose-lowering benefit. 1, 2

Monitoring Requirements

  • Check fasting glucose daily during the titration phase to guide Lantus dose adjustments. 1, 2, 6

  • Measure pre-meal glucose before each meal to calculate correction doses when prandial insulin is added. 1, 2

  • Obtain 2-hour post-prandial glucose after each meal to assess prandial insulin adequacy and guide dose titration. 1, 2

  • Reassess insulin doses every 3 days while actively titrating to avoid therapeutic inertia. 1, 2

  • Check HbA1c every 3 months until stable control is achieved. 1, 6

Hypoglycemia Management

  • Treat any glucose <70 mg/dL immediately with 15 grams of fast-acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1, 2

  • If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20% immediately before the next administration. 1, 2

  • Provide comprehensive patient education on hypoglycemia recognition, treatment, proper injection technique, site rotation, and sick-day management. 1, 2

Critical Pitfalls to Avoid

  • Do not delay adding prandial insulin when HbA1c is 9.5% and average glucose is 172 mg/dL; basal insulin alone will not achieve adequate control at this level of hyperglycemia. 1, 2

  • Do not continue escalating Lantus beyond 0.5 units/kg/day (approximately 35 units) without addressing post-prandial hyperglycemia, as this leads to over-basalization with increased hypoglycemia risk and suboptimal control. 1, 2

  • Do not discontinue metformin when intensifying insulin therapy unless contraindicated, as this leads to higher insulin requirements and greater weight gain. 1, 2

  • Never rely solely on correction (sliding-scale) insulin without scheduled basal and prandial doses; major diabetes guidelines condemn this reactive approach as ineffective and unsafe. 1, 2

Expected Clinical Outcomes

  • With appropriate basal-bolus therapy at weight-based dosing, 68% of patients achieve mean glucose <140 mg/dL versus only 38% with inadequate insulin dosing. 1, 2

  • An HbA1c reduction of 2–3% (from 9.5% to approximately 7–7.5%) is achievable within 3–6 months with intensive insulin titration combined with metformin and SGLT2 inhibitor therapy. 1, 2

  • Properly implemented basal-bolus regimens do not increase overall hypoglycemia incidence compared with inadequate insulin approaches when titrated according to protocol. 1, 2

Related Questions

Is dapagliflozin (SGLT2 inhibitor) safe to use in a patient with type 2 diabetes, dyslipidemia, normal renal function, and newly diagnosed Benign Prostatic Hyperplasia (BPH)?
Is it safe to take Farxiga (dapagliflozin) and minoxidil together?
What is the best management approach for a patient with uncontrolled diabetes, hyperlipidemia, and hypertension who is currently taking Farxiga (dapagliflozin) and is unwilling to take statins?
Is it safe to start Farxiga (dapagliflozin) in a patient with impaired renal function, currently on Losartan (losartan potassium)?
How to manage a patient with uncontrolled diabetes and CHF on insulin degludec, glipizide, and Farxiga (dapagliflozin)?
Which antibiotics should be avoided and which are preferred for treating infections caused by organisms that express basal (constitutive) AmpC beta‑lactamase, such as Enterobacter species, Citrobacter species, Serratia species, and certain Pseudomonas aeruginosa strains?
What is the most likely diagnosis and appropriate management for a child presenting with urticarial‑type rash/vasculitis, fever, abdominal pain, facial edema, leukocytosis, proteinuria (albumin 30 mg/dL) and ketonuria?
What are the indications to discontinue sodium bicarbonate therapy in a patient with chronic kidney disease being treated for metabolic acidosis?
In a patient with a left ventricular assist device (LVAD) who arrests, should standard cardiopulmonary resuscitation (CPR) with chest compressions be performed, and how should hand placement be adjusted to protect the device?
Which thiazide diuretics are appropriate to prescribe for an outpatient with hypertension requiring first‑line therapy?
What is the recommended outpatient antibiotic regimen for uncomplicated typhoid fever, given that I am currently prescribing azithromycin 500 mg twice daily and ciprofloxacin 200 mg twice daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.